Elamipretide TFA
目录号 : GC34569ElamipretideTFA(MTP-131TFA;RX-31TFA;SS-31TFA)是一种靶向作用于线粒体内膜的多肽,是心磷脂过氧化物酶(cardiolipinperoxidase)抑制剂。
Cas No.:1606994-55-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Elamipretide TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA) is a cardiolipin peroxidase inhibitor and mitochondria-targeting peptide[1]. Cardiolipin peroxidase[1]
[1]. Sabbah HN et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206.
Cas No. | 1606994-55-1 | SDF | |
分子式 | C34H50F3N9O7 | 分子量 | 753.81 |
溶解度 | Soluble in Water | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.3266 mL | 6.633 mL | 13.2659 mL |
5 mM | 0.2653 mL | 1.3266 mL | 2.6532 mL |
10 mM | 0.1327 mL | 0.6633 mL | 1.3266 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Antioxidant effect of Elamipretide on bull's sperm cells during freezing/thawing process
Andrology 2021 Jul;9(4):1275-1281.PMID:33675580DOI:10.1111/andr.12996
Background: Spermatozoa are subjected to drastic changes in temperature, ice crystal formation, and diverse types of stresses (chemical, physical, osmotic, and oxidative) during the cryopreservation process, which severely compromise sperm quality and fertility. In this study, we aimed to investigate the protective role of Elamipretide in the cryopreservation of bull's spermatozoa. Materials and methods: The study included 36 healthy Simmental bulls with an average age of 2 ± 0.5 years housed individually in pens. Two ejaculates were collected from each bull using an artificial vagina at 7 a.m. Subsequently, the semen was extended with animal protein-free commercial BIOXcell® extender (IMV Technologies) to a final concentration of 160 × 106 spermatozoa/ml, and rated in terms of motile sperm percentage, progressive motility, viability, and morphological abnormality of spermatozoa. Semen samples that showed more than 60% motility and 60% viability, were selected for the experiment. The fresh semen was then divided into five equal fractions. The first fraction was left for the control group (without Elamipretide), to the next were added in succession 0.1; 1; 5; and 10 μM of Elamipretide TFA (Trifluoroacetic) (MedChemExpress). After that semen was subjected to freezing and thawing. Next semen was assessed for motility, viability, mitochondrial membrane potential and acrosome integrity, and antioxidant activity (SOD, CAT, MDA). Results: It has been shown that a concentration of 5 and 10 μM proved to be the most effective in terms of tested parameters of the quality of sperm cells subjected to cryopreservation. Conclusion: In conclusion, addition of the Elamipretide to the cryopreservation extender significantly improved frozen-thawed sperm cells quality and their function. The results of this study indicate that Elamipretide can be used as a cryoprotective agent to protect cells against the devastating effects of oxidative stress and increasing sperm survival after cryopreservation.